08:18 AM EST, 02/21/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Friday its board authorized a new share repurchase program allowing the company to buy back up to $500 million of its shares.

The company said the new authorization is in addition to the $300 million accelerated repurchase program launched in October 2024, which was completed in early February 2025.

Under the new authorization, the company said repurchases may occur at management's discretion through various methods, including open-market transactions, pre-set trading plans, privately negotiated deals, and accelerated share repurchases, all in line with securities laws.